Rituximab's composition of matter patent in the United States expired in 2016 [1]. This patent, U.S. Patent No. 5,776,456, was set to expire in December 2018, but was subject to patent term extension [2]. However, this extension was invalidated by a court in 2011, bringing the effective expiry date forward to 2013. Subsequently, further legal actions confirmed the expiry of the composition of matter patent in the U.S. by 2016 [3].
When Did Rituximab's Market Exclusivity End?
While the composition of matter patent expired in 2016, market exclusivity for rituximab, marketed as Rituxan by Genentech and Biogen, had already been eroded by earlier legal challenges and the subsequent entry of biosimilars. The loss of patent protection paved the way for the development and approval of biosimilar versions of rituximab in the United States [1][3].
Which Rituximab Biosimilars Are Available in the U.S.?
Several biosimilar versions of rituximab have been approved and launched in the U.S. These include biosimilars referencing the indications for non-Hodgkin's lymphoma and chronic lymphocytic leukemia, as well as rheumatoid arthritis [1][4]. The introduction of these biosimilars has increased treatment options and competition in the market.
How Do Rituximab Biosimilars Compare to the Reference Product?
Biosimilars are approved based on demonstrating high similarity to the reference product (Rituxan) in terms of physicochemical properties, biological activity, and clinical outcomes. While they are highly similar, they are not identical. Approvals consider factors such as safety, purity, and potency. The clinical efficacy and safety profiles of approved rituximab biosimilars are expected to be comparable to the reference product for the approved indications [1][4].
What Was the Impact of Patent Expiry on Rituximab Pricing?
The expiry of rituximab's composition of matter patent and the subsequent introduction of biosimilars have led to a decrease in the overall cost of rituximab therapy in the United States. Biosimilars typically enter the market at a lower price point compared to the originator product, creating price competition and driving down costs for healthcare systems and patients [1][3].
Who Owns Patents for Rituximab?
Genentech, a member of the Roche Group, originally developed and marketed rituximab under the brand name Rituxan. While the composition of matter patent has expired, there may be other patents related to manufacturing processes, formulations, or specific uses of rituximab that could still be in effect. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide details on such intellectual property [2].
What Are the Indications for Rituximab?
Rituximab is approved for the treatment of several conditions, including certain types of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and rheumatoid arthritis. It is also used for granulomatosis with polyangiitis and microscopic polyangiitis [4].
What Are the Side Effects of Rituximab?
Common side effects associated with rituximab treatment include infusion-related reactions, fever, chills, nausea, rash, headache, sore throat, and fatigue. More serious side effects can include reactivation of hepatitis B virus, progressive multifocal leukoencephalopathy (PML), and severe skin reactions [4].
What is the Mechanism of Action of Rituximab?
Rituximab is a chimeric monoclonal antibody that targets the CD20 protein found on the surface of B-lymphocytes. By binding to CD20, rituximab triggers the destruction of these B-cells, which can be beneficial in conditions where B-cells play a role in disease pathology, such as certain cancers and autoimmune diseases [4].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/blog/rituxan-patent-expiration-timeline
[3] https://www.drugpatentwatch.com/blog/rituximab-biosimilars-launch-in-the-us
[4] https://www.drugpatentwatch.com/drug/rituximab